SHORT REPORT

Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study

Teresa Grieco1 | Patrizia Maddalena1 | Alvise Sernicola1 | Rovena Muharremi1 | Stefania Basili2 | Domenico Alvaro2 | Roberto Cangemi2 | Alfredo Rossi1 | Giovanni Pellacani1

1Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, “Sapienza” University of Rome, Rome, Italy
2Department of Translational and Precision Medicine, “Sapienza” University of Rome, Rome, Italy

Correspondence
Alvise Sernicola, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, “Sapienza” University of Rome, Rome, Italy.
Email: alvise.sernicola@uniroma1.it

Abstract
An in-depth characterization of the incidence, morphology, and onset of COVID-19-vaccines cutaneous adverse reactions is currently lacking. The existing literature on COVID-19 vaccination-related cutaneous adverse reactions largely focused on messenger RNA vaccines and mainly included type 1 hypersensitivity reactions, such as urticaria and angioedema. Other cutaneous manifestations are still poorly characterized and have been classified as delayed hypersensitivity rash. Our prospective observational study on a sample of 2740 subjects who underwent the COVID-19 vaccination aimed at defining the prevalence of cutaneous adverse reactions and at identifying their timing of onset and their correlation with the administered dose. Vaccine-related cutaneous adverse reactions occurred in 50 subjects. Patients were asked to complete a questionnaire on the type of COVID-19 vaccine received, the time of onset of cutaneous reactions, and the dates of administration. Out of 2740 individuals who received the COVID-19 vaccination, 50 were diagnosed with cutaneous adverse reactions to vaccine, after the first dose in 28 patients, after the second in 20, and after both in two. We reported localized injection site erythema in 12 patients and generalized cutaneous reactions in 38 patients. Our study shows that cutaneous adverse reactions to COVID-19 vaccination are not common and most often occur after the first dose, recurring infrequently after the second dose. These reactions are usually easily manageable and, even in severe generalized cases, oral antihistamines and corticosteroids were sufficient for resolution. Therefore, except for immediate hypersensitivity reactions, cutaneous adverse reactions do not represent a contraindication to the completion of the vaccination cycle.

KEYWORDS
COVID-19 vaccine, cutaneous adverse reaction, epidemiology, incidence, SARS-CoV-2

INTRODUCTION

Global concern for the COVID-19 outbreak determined the urgency to develop effective vaccines. The first COVID-19 vaccine, Comirnaty™, was granted conditional marketing approval (CMA) on December 21, 2020.1 Authorization for Spikevax™ (previously COVID-19 Vaccine Moderna), for Vaxzevria™ (previously COVID-19 Vaccine AstraZeneca) and for COVID-19 Vaccine Janssen followed on...
January 6, 2021, January 29, 2021 and March 11, 2021, respectively.\textsuperscript{,2,3}

Vaccination schedules involve a single dose for COVID-19 Vaccine Janssen and two doses administered via intramuscular route for the other vaccines; the interval between doses is 21 days for Comirnaty\textsuperscript{™}, 28 days for Spikevax\textsuperscript{™}, and 12 weeks for Vaxzevria\textsuperscript{™}. During the first phase of vaccination, priority was given to healthcare providers and elderly people.

Currently, pivotal phase 3 randomized placebo-controlled trials provided data on the safety of the abovementioned vaccines, including reports of local injection-site reactions, known as “COVID-19 vaccine arm” and consisting in erythema, edema, and pain to the site of injection.\textsuperscript{4}

The existing literature on COVID-19 vaccination-related cutaneous adverse reactions (CARs) has largely focused on mRNA vaccines (Comirnaty\textsuperscript{™} and Spikevax\textsuperscript{™})\textsuperscript{5} and mainly included type 1 hypersensitivity reactions, such as urticaria and angioedema. Other cutaneous manifestations are still poorly characterized and have been classified as delayed hypersensitivity rash.\textsuperscript{6,7}

Except for the recent American Registry systematic report of 414 CARs,\textsuperscript{7} a deeper characterization of the incidence, morphology, and onset of COVID-19-vaccines CARs is lacking.\textsuperscript{5,8}

The objective of our study was, first, to define the prevalence of CARs in our sample; second, to identify the timing of reactions and their correlation with the administered doses (first, second, or both). A third objective was to characterize the cutaneous symptoms and, finally, to report our management of COVID-19 vaccine adverse reactions.

\section{Materials and Methods}

From January to July 2021, we conducted a prospective observational study on a total of 2740 subjects who underwent the COVID-19 vaccination and provided informed consent to use of their details. 2040 (74\%) were health care workers and 700 (26\%) were patients referring to the Department of Dermatology and Allergology of Policlinico Umberto I Hospital-Sapienza University of Rome. 2481 (91\%) of subjects received Comirnaty\textsuperscript{™}, 222 (8\%) Vaxzevria\textsuperscript{™}, and 37 (1\%) Spikevax\textsuperscript{™}. No subject was administered COVID-19 vaccine Janssen that was locally unavailable at the time of the study. Vaccine-related CARs occurred in 50 patients; a thorough skin examination was performed in all patients; in seven cases histology and immunohistochemistry were also carried out to better define the diagnosis. In addition, patients were asked to complete a questionnaire on the type of COVID-19 vaccine received, the time of onset of cutaneous reactions, and the dates of administration. Comorbidities and concomitant therapies were also investigated. Serology and blood tests were carried out to investigate autoimmunity and inflammatory status.

\section{Results}

Out of 2740 individuals who received the COVID-19 vaccination during our observation period, 50 were diagnosed with CARs to vaccine, corresponding to an incidence of 31.28 cases/1000 people-year. Of these, 20 (40\%) were males and 30 (60\%) were females. Mean patients age was 47 (range: 22–76), and all patients were Caucasian. Thirty patients (60\%) had received Comirnaty\textsuperscript{™}, 16 (32\%) Vaxzevria\textsuperscript{™}, and 4 (8\%) Spikevax\textsuperscript{™}.

In 28 patients (56\%) CARs followed the first dose administration; in 20 patients (40\%) and two patients (4\%) CARs followed the second dose administration or both doses, respectively.

Out of 28 patients manifesting CARs after the first dose, eight (29\%) had received Comirnaty\textsuperscript{™}, 16 (57\%) Vaxzevria\textsuperscript{™}, and four (14\%) Spikevax\textsuperscript{™}. Patients manifesting CARs either after the second dose or after both doses had received Comirnaty\textsuperscript{™} (Table 1).

CARs occurred within 7 days from vaccine administration in 34 patients (68\%), within 7–14 days in 13 patients (26\%) and after more than 14 days in three patients (6%). They consisted of localized injection-site erythema in 12 patients (24\%) and generalized

\begin{table}
\centering
\caption{Demographic and clinical characteristics of 50 patients developing CARs, out of 2740 observed subjects that received COVID-19 vaccination (prevalence 1.8\%).}
\begin{tabular}{|l|l|}
\hline
\textbf{Age} & 22.76 years (mean = 47) \\
\hline
\textbf{Sex} & \\
\hline
Female & 30 (60\%) \\
Male & 20 (40\%) \\
\hline
\textbf{Vaccine} & \\
Comirnaty\textsuperscript{™} & 30 (60\%) \\
Vaxzevria\textsuperscript{™} & 16 (32\%) \\
Spikevax\textsuperscript{™} & 4 (8\%) \\
\hline
\textbf{Onset} & \\
After 1st dose & \\
Comirnaty\textsuperscript{™}: 8 (16\%) \\
Vaxzevria\textsuperscript{™}: 16 (32\%) \\
Spikevax\textsuperscript{™}: 4 (8\%) \\
\hline
After 2nd dose & \\
20 (40\%): \\
Comirnaty\textsuperscript{™}: 20 (100\%) \\
\hline
After 1st and 2nd dose & 2 (4\%): \\
Comirnaty\textsuperscript{™}: 2 (100\%) \\
\hline
\textbf{Latency} & \\
<7 days & 34 (68\%) \\
7–14 days & 13 (26\%) \\
>14 days & 3 (6\%) \\
\hline
\textbf{Comorbidities} & \\
Hashimoto’s thyroiditis & 6 (12\%) \\
Anaphylaxis and previous ADR to vaccines & 4 (8\%) \\
Bronchial asthma & 2 (4\%) \\
Chronic kidney disease & 1 (2\%) \\
Coronaropathy & 1 (2\%) \\
Total & 14 (28\%) \\
\hline
\end{tabular}
\end{table}

Abbreviations: ADR, adverse drug reaction; CAR, cutaneous adverse reaction.
TABLE 2  Characterization of cutaneous adverse reactions to COVID-19 vaccines. The timepoints after vaccination and related vaccine doses are reported for each reaction.

| CARs                                      | Frequency | Timepoint (days) | Dose |
|-------------------------------------------|-----------|------------------|------|
| Urticarial rash/angioedema                | 14 (28%)  | <7, 7-14         | 1.2  |
| Local injection site erythema             | 12 (24%)  | <7.7-14          | 1.2  |
| Generalized pruritus                      | 5 (10%)   | 7-14             | 2    |
| Toxic erythema                            | 4 (8%)    | <7               | 2    |
| Erythema multiforme                       | 3 (6%)    | 7-14             | 1    |
| Pityriasis rosea-like eruption            | 3 (6%)    | >14              | 1    |
| Other                                     | 9 (18%)   | <7, 7-14         | 1, 2 |

Note: Other includes Stevens-Johnson syndrome, morbilliform drug exanthema, lymphomatoid drug reaction resembling PLEVA, erythema nodosum, late onset atopic dermatitis, annular lichen planus, pseudo-chilblains, filler injection site reaction, and genital fixed drug eruption. Abbreviation: CAR, cutaneous adverse reaction.

due to selection bias, since females made up 60% of our population sample. Moreover, age of our sample was not very high, as only 6.5% of subjects were aged above 65 years. CARs were chiefly caused by Comirnaty™ (60%), followed by Vaxzevria™ (32%) and Spikevax™ (8%). These percentages are influenced by the prevalence of vaccines administered in our study group; 91% of subjects, including all healthcare workers and elderly vaccinated in our hospital, received Comirnaty™, while 8% and 1% were administered Vaxzevria™ and Spikevax™, respectively. The most common generalized CARs were angioedema and urticarial rashes (28%) that in one patient presented with peculiar involvement of flexural areas and significant photosensitivity. Persistent generalized pruritus without any cutaneous manifestation (10%) and toxic erythema (8%), which is a typical drug-related rash, were also frequent. Less common manifestations consisted in pityriasis rosea-like eruption, 

cutaneous reactions in 38 patients (76%); urticarial rashes and/or angioedema (n = 14; 28%), generalized pruritus (n = 5; 10%), toxic erythema (n = 4; 8%), erythema multiforme (n = 3; 6%), pityriasis rosea-like eruption (n = 3; 6%), Stevens-Johnson syndrome (n = 1; 2%), morbilliform drug exanthema (n = 1; 2%), lymphomatoid drug eruption resembling PLEVA (n = 1; 2%), erythema nodosum (n = 1; 2%), late onset atopic dermatitis (n = 1; 2%), annular lichen planus (n = 1; 2%), pseudo-chilblain relapsing with necrotic features at the second dose (n = 1; 2%), filler injection-site reaction (n = 1; 2%), and genital fixed drug eruption (n = 1; 2%) (Table 2).

Anamnesis revealed that 14 patients (28%) had comorbidities: Hashimoto’s thyroiditis (six patients), past episodes of anaphylaxis and previous adverse reactions to other vaccines (four patients), chronic kidney disease (one patient), coronaropathy (one patient), and bronchial asthma (two patients). No patients reported using anti-inflammatory drugs after vaccine administration. Accurate history obtained from each case allowed us to rule out other plausible causes for the observed reactions. This led us to exclude a case of thoracic herpes zoster in an elderly female patient following the second dose of Comirnaty™: herpes zoster is commonly observed in the elderly and the relationship to the vaccine could not be demonstrated.

4 | DISCUSSION

Our results showed that CARs related to COVID-19 vaccines Comirnaty™, Spikevax™, and Vaxzevria™ are not very common, occurring in about 1.8% of individuals. A limitation of our study was that the majority of the population sample included health care workers; the incidence of CARs—especially local injection-site reactions—may have been underestimated, due to many physicians not seeking dermatological consultation in the presence of mild cutaneous reactions. Patients manifesting CARs were mainly females (60%); however, this may be
REFERENCES
1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603-2615.
2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384:403-416.
3. Cavaleri M, Enzmann H, Straus S, Cooke E. The European medicines Agency’s EU conditional marketing authorisations for COVID-19 vaccines. Lancet. 2021;397:355-357.
4. Johnston MS, Galan A, Watsky KL, Little AJ. Delayed localized hypersensitivity reactions to the Moderna COVID-19 vaccine. JAMA Dermatol. 2021;157:716-720.
5. Farinazzo E, Ponis G, Zelin E, et al. Cutaneous adverse reactions after m-RNA COVID-19 vaccine: early reports from Northeast Italy. J Eur Acad Dermatol Venereol. 2021;35(9):e548–e551.
6. Alpalhão M, Malã-Silva J, Filipe P. Severe acute respiratory syndrome coronavirus 2 vaccines and cutaneous adverse reactions: a review. Dermatitis. 2021;32:133-139.
7. McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol. 2021;85:46-55.
8. Larson V, Seidenberg R, Caplan A, et al. Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination. J Cutan Pathol. 2021. https://doi.org/10.1111/cup.14104
9. Pulitzer MP, Nolan KA, Oshman RG, Phelps RG. CD30+ lymphomatoid drug reactions. Am J Dermatopathol. 2013;35:343-350.
10. Cyrenne BM, Al-Mohammed F, DeKoven JG, Alhusayen R. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35(9):e546–e548.
11. Bowers S, Warshaw EM. Pityriasis lichenoides and its subtypes. J Am Acad Dermatol. 2006;55:557-572.
12. Chello C, Carnicelli G, Sernicola A, et al. Atopic dermatitis in the elderly Caucasian population: diagnostic clinical criteria and review of the literature. Int J Dermatol. 2020;59:716-721.
13. Kounis NG, Koniari I, de Gregorio C, et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccine. 2021;9:221.
14. Restivo V, Candore G, Barrale M, et al. Allergy to polyethilenglicole of anti-SARS CoV2 vaccine recipient: a case report of young adult recipient and the management of future exposure to SARS-CoV2. Vaccine. 2021;9:412.
15. Stingeni L, Bianchi L, Zalaudek I, et al. Adverse cutaneous and mucous reactions from anti SARS-CoV-2 vaccines: recommendations from the Italian Society of Dermatology (SIDeMaST). Ital J Dermatol Venereol. 2021;156:115-117.

How to cite this article: Grieco T, Maddalena P, Sernicola A, et al. Cutaneous adverse reactions after COVID-19 vaccines in a cohort of 2740 Italian subjects: An observational study. Dermatologic Therapy. 2021:e15153. doi:10.1111/dth.15153